$MRKMerck & Co., Inc.

📅 Upcoming

🕒 Recent(90d)

News

• DPHARM: How to address the clinical trial enrollment crisis?
  Clinical trials are facing an enrollment crisis. Around 80% of trials don’t meet their enrollment timelines, and fewer than 5% of eligible adult cancer patients participate in trials.
  fiercebiotech · 18d ago
• Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
  The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."
  biopharma_dive · 18d ago
• Chutes & Ladders—Longtime Takeda R&D chief to depart next June
  Takeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving the company in June after twelve years in the position.
  fiercebiotech · 24d ago
• Spyre tumbles as immune drug misses mark in rheumatoid arthritis
  The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.
  biopharma_dive · 1mo ago
• Hansoh heralds China’s move from ‘follower’ to ‘frontrunner’ in biopharma race
  Hansoh Pharmaceutical has given a bullish assessment of China’s innovative pharma sector, arguing that the industry is “fully transitioning from the ‘follower’ to the ‘frontrunner’ phase.”
  fiercebiotech · 1mo ago
• Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data
  Phase 2 data on Spyre Therapeutics’ anti-TL1A antibody SPY072 in rheumatoid arthritis have fallen short of expectations, prompting the biotech to deprioritize monotherapy development in the indicat…
  fiercebiotech · 1mo ago
• Attovia adds to biotech IPO momentum with $289M offering
  The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.
  biopharma_dive · 2mo ago
• J&J pharma leader to retire; Krystal slumps on gene therapy miss
  Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.
  biopharma_dive · 2mo ago
• FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
  The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduc…
  fda_press · 2mo ago
• Merck ADC, licensed from China, hits mark in first big global trial
  The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.
  biopharma_dive · 4mo ago